OSLO (Reuters) - Three health workers in Norway who recently received the AstraZeneca vaccine against COVID-19 are being treated in hospital for bleeding, blood clots and a low count of blood platelets, Norwegian health authorities said on Saturday.

Norway halted on Thursday the rollout of that vaccine, following a similar move by Denmark. Iceland later followed suit.
We do not know if the cases are linked to the vaccine," Sigurd Hortemo, a senior doctor at the Norwegian Medicines Agency told a news conference held jointly with the Norwegian Institute of Public Health.
All three individuals were under the age of 50.
The European medicine regulator EMA would investigate the three incidents, Hortemo added.
"They have very unusual symptoms: bleeding, blood clots and a low count of blood platelets," Steinar Madsen, Medical Director at the Norwegian Medicines Agency told broadcaster NRK.
AstraZeneca was not immediately available for comment.
Before Denmark's and Norway's move, Austria stopped using a batch of AstraZeneca shots while investigating a death from coagulation disorders and an illness from a pulmonary embolism.
Still, EMA on Thursday said the vaccine's benefits outweighed its risks and could continue to be administered.
Pakistan playing sincere role to mediate between US, Iran: PM Shehbaz
- 14 hours ago

It’s make or break time for AI labeling systems
- 2 hours ago

Trump is waging a silent war on legal immigration
- 2 hours ago
China launches Shenzhou-23 crew mission
- 13 hours ago

Hanging out in my favorite virtual coffee shop in Tokyo
- 2 hours ago
Chinese PM, Field Marshal discuss matters of mutual interest
- 8 hours ago
Why Steve Kerr Stayed With the Warriors
- 44 minutes ago

I have a new go-to browser
- 2 hours ago
Pakistan, China sign agreements, MoUs, cooperation documents
- 14 hours ago
PAF wins 55th National Men's Volleyball Championship 2026
- 14 hours ago
Vibe coding is coming to your phone
- 2 hours ago
Annual Hajj rituals begin in Makkah with arrival of pilgrims in Mina
- 14 hours ago








